Author: Dr. Himanshu Patel, PharmD
Ivermectin has been used for decades as an antiparasitic medication, but researchers continue to investigate whether its biological effects could have applications beyond its established uses. One of the newest areas of interest involves cellular stress, a process that may be particularly important in cancer biology.
In September 2026, researchers published a study examining how ivermectin affects the ability of neuroblastoma cells to recover from cellular stress. The findings provide a new perspective on how ivermectin may interact with cancer-cell biology and highlight a potential pathway for future drug-repurposing research.
What Is Cellular Stress?
Cells constantly encounter challenges, including oxidative stress, changes in their environment, limited nutrients, and exposure to certain chemicals or medications. When cells experience stress, they activate protective mechanisms designed to help them survive.
One response involves the formation of temporary structures called stress granules. Stress granules help temporarily organize RNA and proteins while a cell responds to difficult conditions. Once the stress subsides, healthy cells normally dismantle these structures and resume normal activity.
Researchers are interested in this process because cancer cells often live under stressful conditions as tumors grow and compete for oxygen and nutrients.
What Are Stress Granules?
Stress granules can be thought of as temporary cellular “holding areas.” When a cell is under stress, certain messenger RNAs and proteins become concentrated inside these structures. This can help the cell temporarily reduce normal protein production while protecting important cellular components.
After the stress passes, the granules need to be cleared so the cell can return to normal protein production. This recovery process involves several proteins, including Hsp70, a molecular chaperone involved in helping cells manage damaged or misfolded proteins and recover from stress.
What Did the New Ivermectin Study Find?
The September 2026 study, published in Cells, investigated the effects of ivermectin on human neuroblastoma and cervical carcinoma cell models. Researchers reported that ivermectin delayed the breakdown of stress granules in neuroblastoma cells. They also found that ivermectin reduced the production of new Hsp70 protein during cellular recovery.
Importantly, the researchers did not observe the same Hsp70 effect in the cervical carcinoma cells used in the study. This suggests that the response may depend on the specific cellular context.
The finding is scientifically interesting because it points toward a possible mechanism involving the way cancer cells respond to stress, not simply whether ivermectin directly kills cancer cells.
Why Hsp70 Matters
Hsp70 belongs to a family of proteins known as molecular chaperones. These proteins help other proteins maintain proper structure and assist cells when they are exposed to stressful conditions.
The new research suggests that ivermectin may interfere with the new production of Hsp70 in neuroblastoma cells during recovery from stress. Understanding this mechanism could help researchers investigate whether disrupting cellular stress-recovery systems might eventually become part of new therapeutic strategies. However, this remains an area of investigation rather than an established cancer treatment.
Why This Research Is Important
One reason this study has attracted attention is that it explores a relatively specific biological mechanism. Rather than simply asking whether ivermectin affects cancer cells, researchers are asking:
- How do cancer cells respond to stress?
- How do they recover after stress?
- Which proteins help them survive?
- Could those survival mechanisms represent future research targets?
- Why might different cancer-cell types respond differently?
These questions are part of the broader field of cancer biology and drug repurposing. For an established medication such as ivermectin, discovering a previously unrecognized cellular mechanism can provide researchers with new hypotheses to investigate.
Is Ivermectin a Cancer Treatment?
No. The new study does not establish ivermectin as a cancer treatment. The research was conducted using cell models in the laboratory. It did not demonstrate that ivermectin treats neuroblastoma or any other cancer in human patients. Additional research, including appropriate animal studies and clinical trials, would be needed before researchers could determine whether the findings have therapeutic significance.
In the United States, ivermectin tablets are FDA-approved for certain parasitic infections, including strongyloidiasis and onchocerciasis; cancer is not an FDA-approved indication. The FDA also emphasizes that an approved drug used for an unapproved purpose has not been determined by the agency to be safe and effective for that unapproved use.
What Could Researchers Study Next?
The new findings open several questions for future research. Scientists may investigate whether the cellular-stress mechanism observed in neuroblastoma cells can be reproduced in other models, whether it occurs at clinically relevant drug exposures, and whether interfering with stress-granule recovery could enhance the effects of established cancer therapies.
Future research will also need to determine why some cancer-cell types appear more responsive to this mechanism than others. These steps are essential before laboratory observations can be translated into meaningful clinical research.
The Bigger Picture: Drug Repurposing
Ivermectin is an example of a broader scientific strategy called drug repurposing. Instead of developing an entirely new molecule, researchers investigate whether an existing medication has biological properties that could be relevant to another disease.
Drug repurposing can help scientists identify new research directions because established medications already have substantial information about their pharmacology and approved uses. For patients, however, an interesting research finding should not be confused with a proven treatment. The distinction between laboratory evidence, clinical trials, and established medical practice remains essential.
How Medicine Counter Pharmacy Supports Patients
At Medicine Counter Pharmacy, we believe patients deserve access to safe, reliable, and informed healthcare options. As a licensed U.S. pharmacy, we are committed to responsible medication access and patient-centered care.
We provide access to prescription medications through licensed healthcare providers, with licensed MDs working on our telehealth platform to review and approve prescriptions when appropriate. We also offer high-quality pharmacy products and wellness support, including trusted medications such as Ivermectin and Mebendazole when appropriately prescribed for their established medical uses.
Our approach is centered on safety, education, and informed decision-making. Our goal is to help patients navigate modern healthcare with confidence and clarity while encouraging conversations with qualified healthcare professionals about their individual treatment needs.
Author: Dr. Himanshu Patel, PharmD
Bio: Dr. Himanshu Patel is a Doctor of Pharmacy graduate from the University of Toledo with experience in compounding and community pharmacy. He focuses on personalized medication management and helping patients achieve safe, effective treatment outcomes.
Compounded Ivermectin, Personalized to Your Needs
Our pharmacy offers high-quality compounded Ivermectin prepared in a licensed facility to meet a variety of personalized needs. Each formulation is made with care to support your individual requirements for strength, dosage form, and convenience.
Our pharmacists are available to answer questions and help determine whether a compounded option is appropriate for you. Explore how our customized formulations can fit into your overall care plan based on your provider’s guidance.
Order Ivermectin